To explore the possible mechanism of lj‐2‐66’s anti‐BRAF‐mutant melanoma activity effect, we evaluated the cell cycle and apoptosis in melanoma cells treated with 50 and 100 nM lj‐2‐66 for 48 h by flow cytometry. The gene discussed is BRAF; the disease is melanoma.